was read the article
array:24 [ "pii" => "S1578219012002235" "issn" => "15782190" "doi" => "10.1016/j.adengl.2012.08.012" "estado" => "S300" "fechaPublicacion" => "2012-09-01" "aid" => "569" "copyright" => "Elsevier España, S.L. and AEDV" "copyrightAnyo" => "2011" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2012;103:599-607" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4164 "formatos" => array:3 [ "EPUB" => 39 "HTML" => 3226 "PDF" => 899 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0001731012001020" "issn" => "00017310" "doi" => "10.1016/j.ad.2012.01.008" "estado" => "S300" "fechaPublicacion" => "2012-09-01" "aid" => "569" "copyright" => "Elsevier España, S.L. and AEDV" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2012;103:599-607" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 12962 "formatos" => array:3 [ "EPUB" => 1 "HTML" => 10372 "PDF" => 2589 ] ] "es" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original</span>" "titulo" => "Extracto de <span class="elsevierStyleItalic">Polypodium leucotomos</span> en dermatitis atópica: Ensayo multicéntrico, aleatorizado, doble ciego y controlado con placebo" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "599" "paginaFinal" => "607" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "<span class="elsevierStyleItalic">Polypodium leucotomos</span> Extract in Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1264 "Ancho" => 2278 "Tamanyo" => 233715 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Perfil de asignación de tratamiento y seguimiento del estudio.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A. Ramírez-Bosca, P. Zapater, I. Betlloch, F. Albero, A. Martínez, J. Díaz-Alperi, J.F. Horga" "autores" => array:8 [ 0 => array:2 [ "nombre" => "A." "apellidos" => "Ramírez-Bosca" ] 1 => array:2 [ "nombre" => "P." "apellidos" => "Zapater" ] 2 => array:2 [ "nombre" => "I." "apellidos" => "Betlloch" ] 3 => array:2 [ "nombre" => "F." "apellidos" => "Albero" ] 4 => array:2 [ "nombre" => "A." "apellidos" => "Martínez" ] 5 => array:2 [ "nombre" => "J." "apellidos" => "Díaz-Alperi" ] 6 => array:2 [ "nombre" => "J.F." "apellidos" => "Horga" ] 7 => array:1 [ "colaborador" => "Grupo de Anapsos en Dermatitis Atópica y centros de realización del estudio" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1578219012002235" "doi" => "10.1016/j.adengl.2012.08.012" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219012002235?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731012001020?idApp=UINPBA000044" "url" => "/00017310/0000010300000007/v1_201304241417/S0001731012001020/v1_201304241417/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S1578219012002247" "issn" => "15782190" "doi" => "10.1016/j.adengl.2012.08.013" "estado" => "S300" "fechaPublicacion" => "2012-09-01" "aid" => "573" "copyright" => "Elsevier España, S.L. and AEDV" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2012;103:608-13" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3673 "formatos" => array:3 [ "EPUB" => 50 "HTML" => 2940 "PDF" => 683 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "Amniotic Membrane Transplantation in the Treatment of Chronic Lower Limb Ulcers" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "608" "paginaFinal" => "613" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Aplicación de membrana amniótica en el tratamiento de las úlceras crónicas de extremidades inferiores" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 1002 "Ancho" => 1628 "Tamanyo" => 115623 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Changes in the pain intensity reported by patients following amniotic membrane transplantation.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M. Alsina-Gibert, S. Pedregosa-Fauste" "autores" => array:2 [ 0 => array:2 [ "nombre" => "M." "apellidos" => "Alsina-Gibert" ] 1 => array:2 [ "nombre" => "S." "apellidos" => "Pedregosa-Fauste" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731012001068" "doi" => "10.1016/j.ad.2012.01.010" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731012001068?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219012002247?idApp=UINPBA000044" "url" => "/15782190/0000010300000007/v1_201304241318/S1578219012002247/v1_201304241318/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S1578219012002223" "issn" => "15782190" "doi" => "10.1016/j.adengl.2012.08.011" "estado" => "S300" "fechaPublicacion" => "2012-09-01" "aid" => "564" "copyright" => "Elsevier España, S.L. and AEDV" "documento" => "article" "crossmark" => 0 "subdocumento" => "ssu" "cita" => "Actas Dermosifiliogr. 2012;103:595-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2493 "formatos" => array:3 [ "EPUB" => 43 "HTML" => 1791 "PDF" => 659 ] ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Novelties in Dermatology</span>" "titulo" => "Psoriasis: a Skin Disease Associated With Increased Cardiovascular Risk" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "595" "paginaFinal" => "598" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Psoriasis: una enfermedad cutánea relacionada con riesgo cardiovascular elevado" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M.A. González-Gay, C. González-Vela, C. González-Juanatey" "autores" => array:3 [ 0 => array:2 [ "nombre" => "M.A." "apellidos" => "González-Gay" ] 1 => array:2 [ "nombre" => "C." "apellidos" => "González-Vela" ] 2 => array:2 [ "nombre" => "C." "apellidos" => "González-Juanatey" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731012000634" "doi" => "10.1016/j.ad.2012.01.006" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731012000634?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219012002223?idApp=UINPBA000044" "url" => "/15782190/0000010300000007/v1_201304241318/S1578219012002223/v1_201304241318/en/main.assets" ] "en" => array:21 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Articles</span>" "titulo" => "<span class="elsevierStyleItalic">Polypodium leucotomos</span> Extract in Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "599" "paginaFinal" => "607" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "A. Ramírez-Bosca, P. Zapater, I. Betlloch, F. Albero, A. Martínez, J. Díaz-Alperi, J.F. Horga" "autores" => array:8 [ 0 => array:3 [ "nombre" => "A." "apellidos" => "Ramírez-Bosca" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 1 => array:3 [ "nombre" => "P." "apellidos" => "Zapater" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "I." "apellidos" => "Betlloch" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 3 => array:3 [ "nombre" => "F." "apellidos" => "Albero" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] ] ] 4 => array:3 [ "nombre" => "A." "apellidos" => "Martínez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 5 => array:3 [ "nombre" => "J." "apellidos" => "Díaz-Alperi" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "aff0025" ] ] ] 6 => array:4 [ "nombre" => "J.F." "apellidos" => "Horga" "email" => array:1 [ 0 => "horga_jos@gva.es" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">¿</span>" "identificador" => "cor0005" ] ] ] 7 => array:2 [ "colaborador" => "Grupo de Anapsos en Dermatitis Atópica y centros de realización del estudio" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">◊</span>" "identificador" => "fn0005" ] ] ] ] "afiliaciones" => array:5 [ 0 => array:3 [ "entidad" => "Servicio de Dermatología, Centro Dermatológico Estético de Alicante, Alicante, Spain" "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Unidad de Farmacología Clínica, Hospital General Universitario de Alicante, Instituto de Bioingeniería, Universidad Miguel Hernández, Elche, Alicante, Spain" "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Servicio de Dermatología, Hospital General Universitario de Alicante, Alicante, Spain" "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Servicio de Dermatología, Hospital Virgen de los Lirios, Alcoy, Alicante, Spain" "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] 4 => array:3 [ "entidad" => "ASAC PHARMA, Alicante, Spain" "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "aff0025" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Extracto de <span class="elsevierStyleItalic">Polypodium leucotomos</span> en dermatitis atópica: Ensayo multicéntrico, aleatorizado, doble ciego y controlado con placebo" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0020" "etiqueta" => "Figure 4" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr4.jpeg" "Alto" => 1570 "Ancho" => 2621 "Tamanyo" => 154981 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">A, Changes in atopic dermatitis extent, severity, and symptoms (SCORAD index) over the 6 months of the study. B, Mean Number of flares recorded at each monthly visit. Columns show the median and range for each group and month. SCORAD indicates Scoring Atopic Dermatitis index.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Atopic dermatitis is a chronic inflammatory skin disease characterized by intense pruritus, dry skin, inflammation, and exudate. It is often associated with asthma, allergic rhinitis, food allergy, and recurrent secondary infection. Symptoms usually first appear in childhood, and approximately 50% of cases are diagnosed in the first year of life.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1–3</span></a> In developed countries, atopic dermatitis affects approximately 10% to 15% of children under the age of 5 years at some time, and childhood prevalence is in the range of 10% to 30%.<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2,4</span></a> While the disease tends to be mild, it can have considerable repercussions on the quality of life of both children and adults; its economic and family impact may be higher than that of psoriasis and similar to that of other serious diseases such as early-onset diabetes mellitus.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,2,4,5</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">There is general consensus concerning the treatment of atopic dermatitis in Spain.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,2,6–8</span></a> The primary goals of treatment are to relieve itching, control the inflammation, and prevent relapse. H<span class="elsevierStyleInf">1</span> antihistamines are the treatment of choice for relieving itching. Topical corticosteroids administered daily and calcineurin inhibitors administered in different regimens are used to control inflammation during flares or acute exacerbarations.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,2,6,7</span></a> Hygiene and dietary measures are prescribed to prevent relapse; examples are avoidance of contact with specific triggers and allergens (including food), as well as with nonspecific triggers such as excessive heat and humidity.</p><p id="par0015" class="elsevierStylePara elsevierViewall">The use of topical corticosteroids may be limited by adverse reactions at the application site.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,2,6–9</span></a> More serious systemic adverse effects may also occur but they are much rarer.<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">6,10</span></a> Approximately 70% to 80% of parents or carers of children with atopic dermatitis are concerned about the adverse effects of topical corticosteroids and this leads to reduced treatment adherence; approximately 25% of parents and carers have reported that they avoid topical corticosteroids because of anxiety.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a> New drugs, such as topical calcineurin inhibitors, have emerged as alternatives to corticosteroids to treat inflammation, but there are still safety concerns about the long-term use of these products.<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Polypodium leucotomos</span> (PL) extract is a drug product licensed for the treatment of atopic dermatitis in adults and children of any age; it has been available in Spain for years. The aim of this clinical trial was to determine whether daily administration of PL extract in addition to standard treatment might reduce the use of topical corticosteroids and antihistamines in patients with moderate atopic dermatitis aged between 2 and 17 years who require these drugs to treat flares.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Methods</span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Patients and Randomization</span><p id="par0025" class="elsevierStylePara elsevierViewall">We performed a randomized, double-blind, placebo-controlled, multicenter phase IV study of oral PL extract (Anapsos) administered over 6 months. The study was performed in 9 hospitals in the Autonomous Community of Valencia, Spain (see the members of the Anapsos in Atopic Dermatitis Work Group in Appendix 1). Patients were randomized to receive PL extract or placebo at a ratio of 1:1. Randomization, with stratification per center, was performed electronically prior to initiation of the study. The study protocol (EudraCT 2008-006422-33) complied with the principles of the Declaration of Helsinki (2008) and was approved by the relevant clinical research ethics committees and the Spanish Agency for Medicines and Health Products. Parents or legal guardians and children older than 12 years gave their written consent to being included in the study.</p><p id="par0030" class="elsevierStylePara elsevierViewall">Inclusion criteria were an age of between 2 and 17 years (inclusive) and a diagnosis of atopic dermatitis according to the Hanifin and Rajka criteria.<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a> Disease severity was evaluated using the Scoring Atopic Dermatitis (SCORAD) index.<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">13</span></a> To be included in the study, patients had to have a SCORAD score of 20 to 40 (inclusive) and require or already be using topic corticosteroids to treat atopic dermatitis flares.</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Exclusion Criteria</span><p id="par0035" class="elsevierStylePara elsevierViewall">The main exclusion criteria were pregnancy or breastfeeding; current treatment with phototherapy for atopic dermatitis; treatment with PL extract, systemic corticosteroids, or other systemic or cytostatic immunosuppressants in the previous 2 months; treatment with systemic antimicrobials in the 4 days before the start of the study; fever; severe allergic disease; immunodeficiency disorders or cancer; contraindication for the use of any of the study drugs according to the summaries of product characteristics; known allergy to parabens; concomitant skin disease that could make it difficult to evaluate the atopic dermatitis or that required long-term use of topical corticosteroids; and participation in drug research studies in the 3 months before the start of the study. Women of childbearing age were required to use an effective birth control method if they were or became sexually active during the trial. The criteria for withdrawal was use of corticosteroids for more than 5 days in patients under the age of 10 years and for more than 7 days in patients aged between 10 and 17 years.</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Treatment</span><p id="par0040" class="elsevierStylePara elsevierViewall">The patients received PL extract capsules (Anapsos 120 mg manufactured by Especialidades Farmacéuticas Centrum S.A) or similar placebo capsules produced by the same laboratory. Based on the recommendations of previous studies,<a class="elsevierStyleCrossRefs" href="#bib0070"><span class="elsevierStyleSup">14,15</span></a> the patients were divided into 3 treatment groups according to age (< 6 years, 6-12 years, and >12 years). Children aged less than 6 years received 2 capsules in a single dose at night (240 mg/day of PL extract or placebo); children aged 6 to 12 years received 3 capsules in 2 doses: 1 in the morning and 2 at night (360 mg/day); and children over 12 years received 4 capsules in 2 doses: 2 in the morning and 2 at night (480 mg/day).</p><p id="par0045" class="elsevierStylePara elsevierViewall">Methylprednisolone aceponate 0.1% in emulsion was applied in a thin layer on affected areas to treat flares. Dry skin was treated symptomatically with moisturizing cream after showering or bathing. Patients who required systemic corticosteroids were administered deflazacort at a dosage of 0.25 to 1.5 mg/kg/d. Desloratadine was used to treat pruritus as it comes in tablet and liquid form and dosage could be adjusted to the ages of all the patients in the study. It is administered once daily and because it is a low-sedating antihistamine, it exerts a minimum effect on the sleep loss component of the SCORAD index. The following dosages were used: 2.5 mL of syrup (1.25 mg of desloratadine) once a day in children aged 2 to 5 years; 5 mL (2.5 mg) once a day in children aged 6 to 11 years; and 1 tablet (5 mg) once a day in children aged 12 or over.</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Methods and Study Variables</span><p id="par0050" class="elsevierStylePara elsevierViewall">Thirteen visits, to take place every 2 weeks after the start of treatment, were scheduled once patients had attended the inclusion visit and been assigned to treatment. To collect data on the use of medication, number of flares, and adverse events, the parents or carers were given a diary in which they were asked to note down in detail and objectively any information on the use of medication and the appearance of new health problems. Scheduled blood and urine tests were performed before and after the study. A pregnancy test was performed in patients of child-bearing age before and after the study and once a month for the duration of the study.</p><p id="par0055" class="elsevierStylePara elsevierViewall">The primary outcome measure was the percentage of days on which topical corticosteroids were used in the 6 months in which patients received PL extract or placebo in addition to their standard treatment. Prespecified secondary outcome measures (based on systematically collected data) were changes in the SCORAD index and investigator's global assessment (IGA) 1, 2, 3, 4, 5, and 6 months after the start of treatment; time to first flare (time from randomization to appearance of a new flare); changes in the incidence of flares (based on mean number of flares reported for the 2 months before the baseline visit); and adverse events. A flare was defined as an exacerbation that could be quantified, following evaluation of the patient's diary, physical examination, and an interview with the patient or tutor, with an IGA score of 4 or more, or that required the use of topical corticosteroids for at least 3 days. A course of corticosteroids was defined as the use of corticosteroids according to the prescribed regimen for an interrupted period, regardless of the number of days.</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Statistical Analysis</span><p id="par0060" class="elsevierStylePara elsevierViewall">Continuous quantitative variables were reported as means (SD), categorical variables as numbers and percentages, and time to first flare as a median and range. All the data were analyzed using intention-to-treat analysis (all patients included in the study) and per-protocol analysis (all those who completed follow-up). The last observation carried forward method was used for patients who did not complete follow-up. The percentage of days on which topical corticosteroids or antihistamines were used was calculated as the number of days on which treatment was used divided by the total number of days the study lasted. The PL extract and placebo groups were compared using the Wilcoxon test, with statistical significance set at 5%. Bonferroni adjustment was used for multiple comparisons. Sample size was calculated using data from previous studies of adults with a similar diagnosis and moderate disease in which the placebo group used topical corticosteroids for a mean of 37.2% (34.6%) of days (6-month study period).<a class="elsevierStyleCrossRefs" href="#bib0080"><span class="elsevierStyleSup">16,17</span></a> Assuming thus a 60% reduction in the days topical corticosteroids would be used in the group treated with PL extract and an estimated loss to follow-up of 20%, we calculated that we would need 53 patients per group to detect statistically significant differences for a power of 80%.</p></span></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Results</span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Study Participants</span><p id="par0065" class="elsevierStylePara elsevierViewall">In total, 105 patients (69 girls) were included in the study. Ninety-three patients (89%) completed the 6 months of treatment and the number of withdrawals was similar in the PL extract group and the placebo group. Fifty-two patients were assigned to the PL extract group and 53 to the placebo group (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>). The mean SCORAD score was 31 (95% CI, 30-32). The IGA was classified as mild to moderate in 97% of cases. The mean age of the patients was 8 (4) years (range, 2-17 years), the mean weight was 33.2 (18.8) kg, and the mean axillary temperature was 36.1 (0.6) °C. All the patients met the Hanifin and Rajka diagnostic criteria and most of them met the 4 major criteria. Eighty-eight percent of patients were using topical corticosteroids at the time of the baseline visit. There were no significant differences in demographic characteristics, clinical variables related to atopic dermatitis, or clinical course between the patients in the PL extract group and those in the placebo group (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>).</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Efficacy in Terms of the Reduction in Corticosteroid Use</span><p id="par0070" class="elsevierStylePara elsevierViewall">Topical corticosteroids were used on 11% (12%) of the days in the study period by the patients in the PL extract group and on 12% (11%) of the days by those in the placebo group (<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>.2) (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>). <a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a> also shows a lower use of topical corticosteroids in the PL extract group for all the other variables analyzed but the differences with the placebo group were not significant in any of the cases. <a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>, in turn, shows a lower percentage of patients requiring topical corticosteroids and a lower mean number of courses of treatment in the PL extract group over the course of the study, but again, the differences with the placebo group were not statistically significant.</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0075" class="elsevierStylePara elsevierViewall"><a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a> also shows a progressive reduction in topical corticosteroid use over the 6 months in both groups. In the placebo group, the changes with respect to the previous month were not significant for any of the months analyzed. In the PL group, however, there was a relevant and significant reduction in the second month compared to the first (median of 13.8 days in the first month vs 7.2 days in the second, <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>.012) and in the fifth month compared to the fourth (median of 3 days in the fourth month vs 6 days in the fifth, <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>.012).</p><p id="par0080" class="elsevierStylePara elsevierViewall">On comparing the use of topical steroids each month with that recorded in the first month (by percentage of days), a reduction of 36% was observed in the fifth month for the PL extract group; the corresponding reduction in the placebo group was 9% (<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>.02).</p><p id="par0085" class="elsevierStylePara elsevierViewall">No significant variations in results were seen when the data were adjusted for season.</p></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Efficacy in Terms of Antihistamine Use</span><p id="par0090" class="elsevierStylePara elsevierViewall">Antihistamine and systemic corticosteroid use was evaluated using the same approach as that described for topical corticosteroids. The percentage of days on which the patients took desloratadine over the 6 months was significantly lower in the PL extract group (mean, 14% [19%]; median, 4.5% [range, 0%-66.5%]) than in the placebo group (mean, 21% [22%]; median, 13.6% [range, 0%-86.4% (<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>.038). On analyzing the percentage of days on which desloratadine was used by month, a nonsignificant reduction was seen in the first month and a significant reduction in months 4, 5, and 6 (<a class="elsevierStyleCrossRef" href="#fig0015">Fig. 3</a>A). The overall proportion of patients who required oral antihistamines was also lower in the PL extract group than in the placebo group. This difference was apparent after the first month of treatment but it became statistically significant after the third month (fourth, fifth, and sixth months) (<a class="elsevierStyleCrossRef" href="#fig0015">Fig. 3</a>B).</p><elsevierMultimedia ident="fig0015"></elsevierMultimedia><p id="par0095" class="elsevierStylePara elsevierViewall">No significant between-group differences were observed for the use of systemic corticosteroids (9.6% in the PL extract group vs 13% in the placebo group).</p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Clinical Course</span><p id="par0100" class="elsevierStylePara elsevierViewall"><a class="elsevierStyleCrossRef" href="#fig0020">Fig. 4</a> shows the changes in the SCORAD index and the number of flares each month. The changes in the overall SCORAD index and the 3 subscores (extent, intensity, and pruritus and sleep loss) were similar in both groups. Fewer flares (total number of flares and flares recorded at each visit) were reported in the PL extract group but the differences with the placebo group were slight and statistically insignificant in all cases. There were also no significant differences between the groups in the time to the first flare (median of 0.5 months in both groups) or in the progressive reduction in disease severity assessed using the IGA. In total, 463 adverse events were recorded over the study period: 218 in the PL extract group and 223 in the placebo group. In both groups, most of the events were classified as mild. Moderate adverse events were more common in the placebo group (14 patients) than in the PL extract group (7 patients) (<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>). Only 1 patient, receiving placebo, experienced a severe adverse event (diarrhea with dehydration).</p><elsevierMultimedia ident="fig0020"></elsevierMultimedia><elsevierMultimedia ident="tbl0015"></elsevierMultimedia></span></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Discussion</span><p id="par0105" class="elsevierStylePara elsevierViewall">PL extract is a drug product that increases the proportion of suppressor CD8<span class="elsevierStyleSup">+</span> lymphocytes<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">18</span></a> and modifies cytokine release by inhibiting the proliferation of monocytes and interleukin 1ß, thereby modifying the production of cytokines by T cells, increasing CD4<span class="elsevierStyleSup">+</span> and CD3<span class="elsevierStyleSup">−</span>CD16<span class="elsevierStyleSup">+</span>CD56<span class="elsevierStyleSup">+</span> cells,<a class="elsevierStyleCrossRefs" href="#bib0095"><span class="elsevierStyleSup">19,20</span></a> and stimulating the proliferation and activation of suppressor T cells. It also reduces the effect of CD11, CD18, and CD62-L adhesion molecules.<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">21</span></a> PL extract is effective in different inflammatory<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">22</span></a> and atopic<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">23</span></a> diseases, in particular, atopic dermatitis.<a class="elsevierStyleCrossRefs" href="#bib0075"><span class="elsevierStyleSup">15,24,25</span></a> Our results show that long-term treatment with PL extract is beneficial in pediatric patients with moderate atopic dermatitis (SCORAD score of 20-40) that requires treatment with topical corticosteroids and antihistamines. The most relevant effect of PL extract in our series was a reduction in antihistamine use measured by both the percentage of patients who used desloratadine and the percentage of days on which this drug was used. The clinical improvements noted in the PL extract group, reflected by changes in the SCORAD index, IGA, and number of flares, were similar to those seen in the placebo group, but they were achieved with lower corticosteroid and antihistamine usage. This indicates that the long-term administration of PL extract in addition to standard first-line treatment has both a beneficial effect in the treatment of atopic dermatitis and potential clinical relevance.</p><p id="par0110" class="elsevierStylePara elsevierViewall">The main objective of the study was to investigate whether the administration of PL extract would lead to a reduction in the use of topical corticosteroids, measured by the percentage of days on which these drugs were required. While the daily administration of this drug product over 6 months did reduce the number and percentage of days on which topical corticosteroids, in addition to the percentage of patients who required systemic corticosteroids, the differences with the placebo group were not statistically significant.</p><p id="par0115" class="elsevierStylePara elsevierViewall">In other studies with a similar design to ours, corticosteroid use varied less over the course of treatment, and levels at the end of the 6 months were similar to initial levels.<a class="elsevierStyleCrossRefs" href="#bib0080"><span class="elsevierStyleSup">16,17</span></a> There are, however, certain methodological differences between these studies and ours that may be relevant. First, unlike in our study, the use of antihistamines was not permitted in patients who could not guarantee adherence to a stable treatment regimen for the duration of the study, and second, patients were prescribed topical corticosteroids rather than antihistamines to treat pruritus. The use of topical corticosteroids in these studies was therefore higher in the control group and accordingly there was a greater likelihood that treatment-related differences would reach statistical significance.</p><p id="par0120" class="elsevierStylePara elsevierViewall">The similarities in the overall SCORAD score and the pruritus subscore in the PL extract and placebo groups indicates that PL extract may control pruritus more effectively than antihistamines on demand and that it also may reduce consumption of these drugs. The beneficial effect of PL extract was noted after the first month of treatment and became more noticeable in the last months of the study. The good safety profile of PL extract, which was not associated with a perceivable increase in risk under the study conditions, indicates that it can be prescribed as a long-term treatment. Finally, although we used a second-generation antihistamine (low penetration of blood-brain barrier), it should be noted that first-generation antihistamines are commonly used in routine practice; these cause more drowsiness and are associated with a higher risk of adverse effects in the pediatric population.<a class="elsevierStyleCrossRefs" href="#bib0035"><span class="elsevierStyleSup">7,8</span></a> Our results suggest that PL extract could reduce the risk of adverse effects associated with antihistamines by reducing the consumption of these drugs, although this would need to be confirmed in clinical trials specifically designed to test this hypothesis.</p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Funding</span><p id="par0125" class="elsevierStylePara elsevierViewall">Sponsor: ASAC Pharma. Laboratorios Centrum S. A. Alicante.</p><p id="par0130" class="elsevierStylePara elsevierViewall">This project was cofunded by the 2007-2013 Technological Fund within the European Regional Development Fund Operational Programme and the Spanish Centre for the Development of Industrial Technology (CDTI).</p></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Conflict of Interests</span><p id="par0135" class="elsevierStylePara elsevierViewall">Dr. Ana Ramírez-Bosca is employed at ASAC Pharma.</p><p id="par0140" class="elsevierStylePara elsevierViewall">Dr. Pedro Zapater has worked as a clinical researcher for ASAC Pharma, Novartis, MSD, Generfarma, and Atral.</p><p id="par0145" class="elsevierStylePara elsevierViewall">Dr. Joaquín Díaz-Alperi is employed at ASAC Pharma.</p><p id="par0150" class="elsevierStylePara elsevierViewall">Dr. José F. Horga has worked as a clinical researcher and given talks for ASAC Pharma, Novartis, MSD, Generfarma, Atral, Bioibérica, Abbott, Pfizer, and Lundbeck.</p><p id="par0155" class="elsevierStylePara elsevierViewall">Dr. Isabel Betlloch, Dr. Francisco Albero, and Dr. Asunción Martínez report that they have no conflict of interests.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:11 [ 0 => array:2 [ "identificador" => "xres96165" "titulo" => array:6 [ 0 => "Abstract" 1 => "Introduction" 2 => "Objectives" 3 => "Patients and methods" 4 => "Results" 5 => "Conclusion" ] ] 1 => array:2 [ "identificador" => "xpalclavsec83323" "titulo" => "Keywords" ] 2 => array:2 [ "identificador" => "xres96164" "titulo" => array:6 [ 0 => "Resumen" 1 => "Introducción" 2 => "Objetivos" 3 => "Pacientes y métodos" 4 => "Resultados" 5 => "Conclusiones" ] ] 3 => array:2 [ "identificador" => "xpalclavsec83324" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:3 [ "identificador" => "sec0010" "titulo" => "Methods" "secciones" => array:5 [ 0 => array:2 [ "identificador" => "sec0015" "titulo" => "Patients and Randomization" ] 1 => array:2 [ "identificador" => "sec0020" "titulo" => "Exclusion Criteria" ] 2 => array:2 [ "identificador" => "sec0025" "titulo" => "Treatment" ] 3 => array:2 [ "identificador" => "sec0030" "titulo" => "Methods and Study Variables" ] 4 => array:2 [ "identificador" => "sec0035" "titulo" => "Statistical Analysis" ] ] ] 6 => array:3 [ "identificador" => "sec0040" "titulo" => "Results" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "sec0045" "titulo" => "Study Participants" ] 1 => array:2 [ "identificador" => "sec0050" "titulo" => "Efficacy in Terms of the Reduction in Corticosteroid Use" ] 2 => array:2 [ "identificador" => "sec0055" "titulo" => "Efficacy in Terms of Antihistamine Use" ] 3 => array:2 [ "identificador" => "sec0060" "titulo" => "Clinical Course" ] ] ] 7 => array:2 [ "identificador" => "sec0065" "titulo" => "Discussion" ] 8 => array:2 [ "identificador" => "sec0070" "titulo" => "Funding" ] 9 => array:2 [ "identificador" => "sec0075" "titulo" => "Conflict of Interests" ] 10 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2011-07-19" "fechaAceptado" => "2012-01-29" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec83323" "palabras" => array:4 [ 0 => "Atopic dermatitis" 1 => "<span class="elsevierStyleItalic">Polypodium leucotomos</span> extract" 2 => "Topical Corticosteroids" 3 => "Antihistamines" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec83324" "palabras" => array:4 [ 0 => "Dermatitis atópica" 1 => "extracto de <span class="elsevierStyleItalic">Polypodium leucotomos</span>" 2 => "Corticosteroides tópicos" 3 => "Antihistamínicos" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<span class="elsevierStyleSectionTitle">Introduction</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Topical corticosteroids are used to treat inflammation and relieve itching in atopic dermatitis, but their use is limited by adverse reactions.</p> <span class="elsevierStyleSectionTitle">Objectives</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">The main aim of this study was to investigate whether daily treatment with <span class="elsevierStyleItalic">Polypodium leucotomos</span> extract would reduce the use of topical corticosteroids in children and adolescents with atopic dermatitis. We also analyzed oral antihistamine use and changes in disease severity.</p> <span class="elsevierStyleSectionTitle">Patients and methods</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">We performed a phase IV randomized, double-blind, placebo-controlled, multicenter trial involving 105 patients aged between 2 and 17 years who were receiving topical corticosteroids to treat moderate atopic dermatitis. The patients were randomized to receive, in addition to their standard treatment, <span class="elsevierStyleItalic">Polypodium leucotomos</span> extract or placebo (both in capsule form) for 6 months. The percentage of days on which topical corticosteroids and other atopic dermatitis treatments were used was calculated.</p> <span class="elsevierStyleSectionTitle">Results</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Use of <span class="elsevierStyleItalic">Polypodium leucotomos</span> extract did not significantly reduce the mean (SD) percentage of days on which topical corticosteroids were used (11% [12%] vs 12% [11%] for placebo). A significant reduction was, however, observed for oral histamine use (median percentage of days, 4.5% in the <span class="elsevierStyleItalic">Polypodium leucotomos</span> group and 13.6% in the placebo group [<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>.038]). The percentage of patients who used oral antihistamines was also lower in the <span class="elsevierStyleItalic">Polypodium leucotomos</span> group.</p> <span class="elsevierStyleSectionTitle">Conclusion</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Long-term treatment with <span class="elsevierStyleItalic">Polypodium leucotomos</span> extract has benefits for children and adolescents with atopic dermatitis who require pharmacologic treatment to reduce inflammation and relieve itching.</p>" ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<span class="elsevierStyleSectionTitle">Introducción</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Para el control de la lesión inflamatoria de la dermatitis atópica, y secundariamente del prurito, se utilizan corticosteroides tópicos, pero su empleo está limitado por las reacciones adversas.</p> <span class="elsevierStyleSectionTitle">Objetivos</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">El objetivo primario del estudio fue evaluar si el tratamiento diario con extracto de <span class="elsevierStyleItalic">Polypodium leucotomos</span> permitiría reducir el uso de corticosteroides tópicos en niños y adolescentes con dermatitis atópica. Secundariamente se valoró el consumo de antihistamínicos orales, así como la evolución de la enfermedad.</p> <span class="elsevierStyleSectionTitle">Pacientes y métodos</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Se ha realizado un ensayo clínico en fase <span class="elsevierStyleSmallCaps">iv</span>, multicéntrico, aleatorizado y doble ciego de extracto de <span class="elsevierStyleItalic">Polypodium leucotomos</span>, controlado con placebo, en 105 pacientes de 2 a 17 años de edad, con dermatitis atópica de intensidad moderada e indicación de corticosteroides tópicos. Los pacientes recibieron durante 6 meses extracto de <span class="elsevierStyleItalic">Polypodium leucotomos</span> o placebo por vía oral añadidos al protocolo terapéutico habitual, y se calculó el porcentaje de días en que se utilizaban corticosteroides tópicos u otros tratamientos para la dermatitis atópica.</p> <span class="elsevierStyleSectionTitle">Resultados</span><p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">El extracto de <span class="elsevierStyleItalic">Polypodium leucotomos</span> redujo de modo no significativo el uso de corticosteroides tópicos (11<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>12% de días), comparado con placebo (12<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>11%). El porcentaje de días en los que los pacientes requirieron antihistamínicos orales fue significativamente menor con extracto de <span class="elsevierStyleItalic">Polypodium leucotomos</span> (mediana de 4,5% días) que con placebo (13,6%) (p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,038). También se redujo el porcentaje de pacientes que tomaron antihistamínicos orales.</p> <span class="elsevierStyleSectionTitle">Conclusiones</span><p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">El tratamiento prolongado con extracto de <span class="elsevierStyleItalic">Polypodium leucotomos</span> aporta beneficios relevantes para los pacientes en edad pediátrica con dermatitis atópica que precisan tratamiento farmacológico para controlar la lesión inflamatoria y reducir el prurito.</p>" ] ] "NotaPie" => array:2 [ 0 => array:2 [ "etiqueta" => "◊" "nota" => "<p class="elsevierStyleNotepara">At the end of the article is attached an Annex 1 with the members of the working group.</p>" ] 1 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara">Please cite this article as: Ramírez-Bosca A, Zapater P, Betlloch I, Albero F, Martínez A, Díaz-Alperi J, Horga JF, y Grupo de Anapsos en Dermatitis Atópica y centros de realización del estudio. Actas Dermosifiliogr.2012;103:599–607.</p>" ] ] "apendice" => array:1 [ 0 => array:1 [ "seccion" => array:1 [ 0 => array:4 [ "apendice" => "<p id="par0160" class="elsevierStylePara elsevierViewall">Francisco Albero: Dermatology, Hospital Virgen de los Lirios de Alcoy (Alicante, Spain). Milagros Azorín: Dermatology, Centro de Especialidades Babel de Alicante. Isabel Betlloch: Dermatology, Hospital General Universitario de Alicante. Pedro Devesa: Dermatology, Hospital General Universitario de Elche (Alicante, Spain). Joaquín Díaz-Alperi: ASAC PHARMA, Alicante. Pedro M. Genovi: Dermatology, Hospital Marina Baixa (Alicante, Spain). José F. Horga: Unidad de Farmacología Clínica, Hospital General Universitario de Alicante e Instituto de Bioingeniería de la Universidad Miguel Hernández (Elche, Alicante, Spain). Asunción Martínez: Dermatology, Centro Dermatológico Estético de Alicante. Concha Más: Dermatology, private practice (Alicante, Spain). Conrad Pujol: Dermatology, Hospital Universitario La Fe, Valencia. Ana Ramírez: Dermatology, Centro Dermatológico Estético de Alicante. Eugenio Salgado: Dermatology, private practice (Alicante, Spain). Pedro Zapater: Clinical Pharmacology Unit, Hospital General Universitario de Alicante, Instituto de Bioingeniería, Universidad Miguel Hernández (Elche, Alicante, Spain).</p>" "etiqueta" => "Appendix A" "titulo" => "Anapsos in Atopic Dermatitis Working Group and Study Centers" "identificador" => "sec0080" ] ] ] ] "multimedia" => array:7 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1261 "Ancho" => 2237 "Tamanyo" => 196656 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Flow diagram showing treatment allocation and follow-up.</p>" ] ] 1 => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 927 "Ancho" => 2688 "Tamanyo" => 129817 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">A, Percentage of patients who required treament with topical corticosteroids during the study. B, Number of courses of treatment required.</p>" ] ] 2 => array:7 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 906 "Ancho" => 2654 "Tamanyo" => 132800 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Use of oral antihistamines during the 6 months of the study. A, Mean percentage of days on which the patients in the <span class="elsevierStyleItalic">Polypodium leucotomos</span> extract and the placebo group took oral antihistamines. B, Percentage of patients who took oral antihistamines every month. * <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>.05 on comparing data from the same month between groups.</p>" ] ] 3 => array:7 [ "identificador" => "fig0020" "etiqueta" => "Figure 4" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr4.jpeg" "Alto" => 1570 "Ancho" => 2621 "Tamanyo" => 154981 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">A, Changes in atopic dermatitis extent, severity, and symptoms (SCORAD index) over the 6 months of the study. B, Mean Number of flares recorded at each monthly visit. Columns show the median and range for each group and month. SCORAD indicates Scoring Atopic Dermatitis index.</p>" ] ] 4 => array:7 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "leyenda" => "<p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">Abbreviations: IGA, investigator's general assessment; SCORAD, Scoring Atopic Dermatitis index.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">Polypodium leucotomos</span> Extract Group (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>52) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Placebo Group (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>53) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">P</span> \t\t\t\t\t\t\n \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Mean (SD) age, y</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7.45 (4.5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">8.1 (4.5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">.493 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="4" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Distribution by age, No. of patients</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>2-6 y \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">25 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">20 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>6-12 y \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">18 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">22 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>>12 y \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">11 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="4" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Girls, No. (%)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">36 (69) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">33 (62) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">.539 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Mean (SD) weight, kg</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">31.8 (17.9) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">34.2 (19.7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">.390 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Mean (SD) height, cm</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">126 (27) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">129 (27) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">.482 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Mean (SD) axillary temperature</span>, °C \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">36.1 (0.6) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">36.1 (0.6) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">.904 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Mean (SD) SCORAD score</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">30.0 (6.5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">32.2 (5.6) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">.07 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="4" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">IGA, No. (%) of patients</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">.430 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Practically clear \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (1.9) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (1.9) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Mild \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">17 (32.7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">11 (20.8) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Moderate \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">34 (65.4) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">40 (75.5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Severe \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (1.9) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="4" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Using topical corticosteroids at start of study, No. (%) of patients</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">43 (83) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">49 (93) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">.223 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab182303.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">Baseline Characteristics of Study Participants.</p>" ] ] 5 => array:7 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "leyenda" => "<p id="spar0090" class="elsevierStyleSimplePara elsevierViewall">Abbreviation: NS, nonsignificant difference.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">Polypodium leucotomos</span> Extract \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Placebo \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Mean (SD) topical corticosteroid use, % of days (intention-to-treat analysis) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">11 (12) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12 (11) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NS \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Mean (SD) topical corticosteroid use, No. of days (intention-to-treat analysis) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">19 (21) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">22 (19) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NS \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Mean (SD) topical corticosteroid use, % of days (per-protocol analysis) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">21 (19) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">26 (21) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NS \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Mean (SD) topical corticosteroid use, No. of days (per-protocol analysis) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">33 (31) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">45 (37) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NS \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Mean topical corticosteroid use, No. of courses \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4.3 (4.1) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5.6 (4.3) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NS \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Systemic corticosteroid use, % of patients \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">9.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">13 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NS \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab182301.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0085" class="elsevierStyleSimplePara elsevierViewall">Corticosteroid Use During the Study.</p>" ] ] 6 => array:7 [ "identificador" => "tbl0015" "etiqueta" => "Table 3" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "leyenda" => "<p id="spar0100" class="elsevierStyleSimplePara elsevierViewall">Abbreviation: NS, nonsignificant difference.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">Polypodium leucotomos</span> Extract Group (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Placebo Group (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>15) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Moderate \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">• Broncospasm episode• Lip swelling• Chickenpox• Cold• Pharyngoamigalitis (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>2)• Cough and cold \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">• Diarrhea• Flu-bronchitis (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>3)• Fever (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>2)• Pharyngotonsillitis• Acute flare of atopic dermatitis• Intense pruritus• Tinea capitis• Eczema superinfection• Back pain• Mesenteric adenitis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NS \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Serious \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">• Diarrhea with dehydration \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NS \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab182302.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0095" class="elsevierStyleSimplePara elsevierViewall">Moderate to Severe Adverse Events During Study.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:25 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Internacional consensus conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "The ICCAD II Faculty" "etal" => false "autores" => array:2 [ 0 => "C. Ellis" 1 => "T. Lugar" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2003" "volumen" => "148" "numero" => "Suppl 3" "paginaInicial" => "3" "paginaFinal" => "10" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12694268" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Dermatitis atópica infantil: revisión y actualización" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A. Conde-Toboada" 1 => "F.J. González Barcala" 2 => "J. Toribio" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Actas Dermosifilogr" "fecha" => "2008" "volumen" => "99" "paginaInicial" => "690" "paginaFinal" => "700" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Atopic dermatitis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "T. Bieber" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMra074081" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2008" "volumen" => "358" "paginaInicial" => "1483" "paginaFinal" => "1494" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18385500" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The epidemiology of atopic dermatitis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "R.M. Levy" 1 => "J.M. Gelfand" 2 => "A.C. Yan" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Clin Dermatol" "fecha" => "2003" "volumen" => "21" "paginaInicial" => "109" "paginaFinal" => "115" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12706328" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Atopic eczema: its impact on the family and financial cost" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "J.C. Su" 1 => "A.S. Kemp" 2 => "G.A. Varigos" 3 => "T.M. Nolan" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Arch Dis Child" "fecha" => "1997" "volumen" => "76" "paginaInicial" => "159" "paginaFinal" => "162" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9068310" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "National Institute for health and clinical excellence. Atopic eczema in children. Management of atopic eczema in children from birth up to the age of 12 years. NICE clinical guideline 57 [accessed Dec 2007]. Available at: <a class="elsevierStyleInterRef" href="http://www.nice.org.uk/nicemedia/pdf/CG057FullGuideline.pdf">http://www.nice.org.uk/nicemedia/pdf/CG057FullGuideline.pdf</a>" ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Dermatitis atópica: clínica, diagnóstico diferencial y tratamiento" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "M. Ridao" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Pediatr Integral" "fecha" => "2004" "volumen" => "8" "paginaInicial" => "204" "paginaFinal" => "210" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Dermatitis atópica en la edad infantil. Valoración de la gravedad y su tratamiento" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "F. Muñoz" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "JANO" "fecha" => "2002" "volumen" => "1432" "paginaInicial" => "52" "paginaFinal" => "57" ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Glucocorticoid therapy-induced skin atrophy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "S. Schoepe" 1 => "H. Schäcke" 2 => "E. May" 3 => "K. Asadullah" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.0906-6705.2006.00435.x" "Revista" => array:6 [ "tituloSerie" => "Exp Dermatol" "fecha" => "2006" "volumen" => "15" "paginaInicial" => "406" "paginaFinal" => "420" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16689857" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Adverse effects of topical corticosteroids use" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "D.A. Fisher" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "West J Med" "fecha" => "1995" "volumen" => "162" "paginaInicial" => "123" "paginaFinal" => "126" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7794369" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Calcineurin inhibitors in the treatment of allergic dermatitis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "A.P. Castro" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "J Pediatr" "fecha" => "2006" "volumen" => "82" "numero" => "S5" "paginaInicial" => "166" "paginaFinal" => "172" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/4681859" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Diagnosis features of atopic dermatitis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "J.M. Hanifin" 1 => "G. Rajka" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Acta Derm Venereol" "fecha" => "1980" "volumen" => "92" "paginaInicial" => "44" "paginaFinal" => "47" ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Severity scoring of atopic dermatitis: the SCORAD index" "autores" => array:1 [ 0 => array:2 [ "colaboracion" => "European Task Force on Atopic Dermatitis" "etal" => false ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Dermatology" "fecha" => "1993" "volumen" => "186" "paginaInicial" => "23" "paginaFinal" => "31" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8435513" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Beltran B, Martínez BP, Ruiz FJ. Nuevo tratamiento efectuado con 130 niños afectados de dermatitis atópica. XIII Congreso Nacional Sociedad Española de Alergia e Inmunología Clínica. Sevilla; 1983." ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Reducción en el consumo de corticoides tópicos en pacientes con dermatitis atópica tratados con anapsos. Descripción de una serie de casos" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "A. Ramírez-Boscá" 1 => "A. Martínez" 2 => "M. González" 3 => "J. Gosálbez" 4 => "J. Ballester" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "Doyma Update" "fecha" => "2008" ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0080" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "CASM-DE-01 study group. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "M. Meurer" 1 => "R. Fölster-Holst" 2 => "G. Wozel" 3 => "G. Weidinger" 4 => "M. Jünger" 5 => "M. Bräutigam" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "65863" "Revista" => array:6 [ "tituloSerie" => "Dermatology" "fecha" => "2002" "volumen" => "205" "paginaInicial" => "271" "paginaFinal" => "277" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12399676" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0085" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "CASM-DE-01 Study Group" "etal" => true "autores" => array:6 [ 0 => "M. Meurer" 1 => "M. Fartasch" 2 => "G. Albrecht" 3 => "T. Vogt" 4 => "M. Worm" 5 => "T. Ruzicka" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1159/000078462" "Revista" => array:6 [ "tituloSerie" => "Dermatology" "fecha" => "2004" "volumen" => "208" "paginaInicial" => "365" "paginaFinal" => "372" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15178928" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0090" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Anapsos, an antipsoriatic drug which increases the proportion of suppresor cells in human peripheral blood" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "J. Vargas" 1 => "C. Muñoz" 2 => "C. Osorio" 3 => "E. García-Olivares" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Ann Immunol" "fecha" => "1983" "volumen" => "134C" "paginaInicial" => "393" "paginaFinal" => "400" ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0095" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of Anapsos (<span class="elsevierStyleItalic">Polypodium leucotomos</span> extract) on in vitro production of cytokines" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "J.M. Sempere" 1 => "C. Rodrigo" 2 => "A. Campos" 3 => "J.F. Villalba" 4 => "J. Diaz" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Br J Clin Pharmacol" "fecha" => "1997" "volumen" => "43" "paginaInicial" => "85" "paginaFinal" => "89" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9056057" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0100" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efectos de Anapsos sobre la producción <span class="elsevierStyleItalic">in vitro</span> de citocinas en células mononucleares de sangre periférica humanas" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "J.M. Sempere" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Natura Medicatrix" "fecha" => "1998" "volumen" => "49" "paginaInicial" => "38" "paginaFinal" => "40" ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0105" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Anapsos (<span class="elsevierStyleItalic">Polypodium leucotomos</span>) modulates lymphoid cells and the expression of adhesion molecules" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.M. Sempere-Ortells" 1 => "A. Campos" 2 => "I. Velasco" 3 => "F. Marco" 4 => "A. Ramirez-Bosca" 5 => "J. Diaz" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Pharmacol Res" "fecha" => "2002" "volumen" => "46" "paginaInicial" => "185" "paginaFinal" => "190" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12220959" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0110" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Modification of the inflammatory activity of psoriatic arthritis in patients treated with extract of Polipodium leucotomos (Anapsos)" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "F.J. Navarro-Blasco" 1 => "J.M. Sempere" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Br J Rheumatol" "fecha" => "1998" "volumen" => "37" "paginaInicial" => "912" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9734686" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0115" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Anapsos, una nueva orientación terapéutica en las manifestaciones digestivas del estado atópico" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "M. López" 1 => "J.F. Vargas" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Acta Ped Esp" "fecha" => "1988" "volumen" => "46" "paginaInicial" => "556" "paginaFinal" => "561" ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0120" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Anapsos modifies immunological parameters and improves the clinical course in atopic dermatitis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "D. Jiménez" 1 => "E. Doblare" 2 => "R. Naranjo" 3 => "C. Muñoz" 4 => "J.F. Vargas" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Dermatologica" "fecha" => "1986" "volumen" => "173" "paginaInicial" => "154" "paginaFinal" => "155" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/3533665" "web" => "Medline" ] ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0125" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Anapsos, an antipsoriatic drug, in atopic dermatitis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "D. Jiménez" 1 => "R. Naranjo" 2 => "E. Doblare" 3 => "C. Muñoz" 4 => "J.F. Vargas" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Allergol Immunopathol (Madr)" "fecha" => "1987" "volumen" => "15" "paginaInicial" => "185" "paginaFinal" => "189" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/15782190/0000010300000007/v1_201304241318/S1578219012002235/v1_201304241318/en/main.assets" "Apartado" => array:4 [ "identificador" => "6155" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Original Articles" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15782190/0000010300000007/v1_201304241318/S1578219012002235/v1_201304241318/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219012002235?idApp=UINPBA000044" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 November | 20 | 11 | 31 |
2024 October | 130 | 61 | 191 |
2024 September | 124 | 44 | 168 |
2024 August | 181 | 91 | 272 |
2024 July | 202 | 40 | 242 |
2024 June | 138 | 67 | 205 |
2024 May | 116 | 55 | 171 |
2024 April | 120 | 42 | 162 |
2024 March | 104 | 61 | 165 |
2024 February | 94 | 45 | 139 |
2024 January | 97 | 35 | 132 |
2023 December | 65 | 20 | 85 |
2023 November | 68 | 44 | 112 |
2023 October | 80 | 40 | 120 |
2023 September | 65 | 50 | 115 |
2023 August | 58 | 38 | 96 |
2023 July | 56 | 42 | 98 |
2023 June | 87 | 30 | 117 |
2023 May | 78 | 26 | 104 |
2023 April | 75 | 28 | 103 |
2023 March | 63 | 29 | 92 |
2023 February | 56 | 28 | 84 |
2023 January | 49 | 49 | 98 |
2022 December | 79 | 41 | 120 |
2022 November | 50 | 26 | 76 |
2022 October | 46 | 30 | 76 |
2022 September | 42 | 56 | 98 |
2022 August | 28 | 45 | 73 |
2022 July | 29 | 33 | 62 |
2022 June | 49 | 41 | 90 |
2022 May | 102 | 48 | 150 |
2022 April | 72 | 58 | 130 |
2022 March | 71 | 66 | 137 |
2022 February | 72 | 36 | 108 |
2022 January | 72 | 58 | 130 |
2021 December | 61 | 40 | 101 |
2021 November | 71 | 46 | 117 |
2021 October | 87 | 73 | 160 |
2021 September | 57 | 52 | 109 |
2021 August | 69 | 23 | 92 |
2021 July | 66 | 39 | 105 |
2021 June | 64 | 33 | 97 |
2021 May | 78 | 53 | 131 |
2021 April | 221 | 138 | 359 |
2021 March | 117 | 42 | 159 |
2021 February | 127 | 29 | 156 |
2021 January | 82 | 20 | 102 |
2020 December | 96 | 27 | 123 |
2020 November | 60 | 17 | 77 |
2020 October | 42 | 18 | 60 |
2020 September | 39 | 15 | 54 |
2020 August | 29 | 26 | 55 |
2020 July | 42 | 15 | 57 |
2020 June | 44 | 45 | 89 |
2020 May | 34 | 29 | 63 |
2020 April | 49 | 23 | 72 |
2020 March | 41 | 25 | 66 |
2020 February | 7 | 4 | 11 |
2020 January | 0 | 2 | 2 |
2019 December | 4 | 8 | 12 |
2019 November | 0 | 2 | 2 |
2019 October | 0 | 2 | 2 |
2019 September | 4 | 4 | 8 |
2019 August | 0 | 1 | 1 |
2019 July | 2 | 7 | 9 |
2019 June | 2 | 12 | 14 |
2019 May | 9 | 23 | 32 |
2019 April | 15 | 1 | 16 |
2019 March | 3 | 10 | 13 |
2019 February | 2 | 0 | 2 |
2019 January | 4 | 0 | 4 |
2018 December | 4 | 0 | 4 |
2018 November | 6 | 0 | 6 |
2018 October | 4 | 0 | 4 |
2018 September | 5 | 0 | 5 |
2018 March | 9 | 3 | 12 |
2018 February | 59 | 12 | 71 |
2018 January | 60 | 9 | 69 |
2017 December | 63 | 9 | 72 |
2017 November | 52 | 10 | 62 |
2017 October | 53 | 4 | 57 |
2017 September | 65 | 6 | 71 |
2017 August | 66 | 9 | 75 |
2017 July | 64 | 3 | 67 |
2017 June | 85 | 14 | 99 |
2017 May | 75 | 5 | 80 |
2017 April | 74 | 11 | 85 |
2017 March | 52 | 11 | 63 |
2017 February | 51 | 11 | 62 |
2017 January | 42 | 9 | 51 |
2016 December | 52 | 6 | 58 |
2016 November | 74 | 9 | 83 |
2016 October | 88 | 22 | 110 |
2016 September | 108 | 19 | 127 |
2016 August | 115 | 16 | 131 |
2016 July | 61 | 34 | 95 |
2016 June | 11 | 14 | 25 |
2016 May | 18 | 24 | 42 |
2016 April | 10 | 6 | 16 |
2016 March | 19 | 4 | 23 |
2016 February | 20 | 4 | 24 |
2016 January | 14 | 2 | 16 |
2015 December | 13 | 11 | 24 |
2015 November | 21 | 9 | 30 |
2015 October | 18 | 2 | 20 |
2015 September | 10 | 3 | 13 |
2015 August | 24 | 4 | 28 |
2015 July | 79 | 1 | 80 |
2015 June | 79 | 12 | 91 |
2015 May | 132 | 14 | 146 |
2015 April | 99 | 15 | 114 |
2015 March | 86 | 20 | 106 |
2015 February | 65 | 15 | 80 |
2015 January | 72 | 14 | 86 |
2014 December | 84 | 9 | 93 |
2014 November | 74 | 12 | 86 |
2014 October | 80 | 19 | 99 |
2014 September | 75 | 17 | 92 |
2014 August | 32 | 5 | 37 |
2014 July | 28 | 12 | 40 |
2014 June | 52 | 14 | 66 |
2014 May | 62 | 16 | 78 |
2014 April | 48 | 10 | 58 |
2014 March | 50 | 19 | 69 |
2014 February | 51 | 23 | 74 |
2014 January | 73 | 15 | 88 |
2013 December | 38 | 11 | 49 |
2013 November | 20 | 20 | 40 |
2013 October | 23 | 15 | 38 |
2013 September | 20 | 14 | 34 |
2013 August | 17 | 20 | 37 |
2013 July | 20 | 24 | 44 |
2013 June | 17 | 42 | 59 |
2013 May | 15 | 20 | 35 |
2013 April | 15 | 27 | 42 |
2013 March | 20 | 23 | 43 |
2013 February | 40 | 6 | 46 |
2013 January | 27 | 7 | 34 |
2012 December | 18 | 8 | 26 |
2012 November | 2 | 3 | 5 |
2012 October | 2 | 5 | 7 |
2012 September | 0 | 2 | 2 |